ArticleTherapeutic advances in drug safety2025
Interdisciplinary pharmaceutical care model engaging patient participation alleviate the anticholinergic burden in community-dwelling older adults: subgroup analysis of a randomized controlled trial.
Article in Therapeutic advances in drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drugs with anticholinergic (AC) effects can cause adverse reactions such as dry mouth, blurred vision, urinary retention, and cognitive impairment, and have been linked to poorer health outcomes, including reduced quality of life, higher mortality, and longer hospital stays. Older adults are particularly susceptible due to age-related changes, and polypharmacy may further increase risk. While tools exist to identify anticholinergic burden (ACB), real-world management remains challenging. Pharmacist-led or multidisciplinary reviews can reduce ACB, but such interventions are uncommon in rural community settings and often overlook patients' perspectives, despite evidence supporting patient-centered approaches. Objectives: AC drugs can increase ACB and have negative effects on older adults. This study evaluated the impact of interdisciplinary pharmaceutical care integrated with older adults' engagement on reducing ACB in rural communities. Design: Subgroup analysis of the Healthy Longevity and Aging in Place community-based cluster-randomized controlled trial conducted in rural Yunlin, Taiwan, focusing on the pharmaceutical care component for residents aged ⩾50 years. Methods: Communities were randomized (1:1) to receive either an interdisciplinary pharmaceutical care program or usual care. The care team, comprising physicians, pharmacists, and nurses, reviewed participants' medications, categorized AC drugs as for chronic disease control (R-type) or symptom relief (S-type), and delivered patient-specific recommendations, education, and follow-up over 6 months. The primary outcome was the proportion of AC drug discontinuation at 6 months. Results: Three hundred and forty-six community-dwelling older adults were included in the analyses; 56% of the elderly were prescribed AC drugs, and 337 AC drugs were analyzed. After 6 months of intervention, the pharmaceutical care group had a higher overall discontinuation rate (22%) compared with the usual care group (14%); while this difference was not statistically significant ( Conclusion: This community-based interdisciplinary pharmaceutical care model, which included patient participation, was effective in reducing the burden of S-type AC drugs among older adults in rural communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.